Scientists at St. Jude Children’s Research Hospital comprehensively identified genes directly regulated by a protein associated with high-risk pediatric leukemias.
Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma
CHICAGO — Combination neoadjuvant immunotherapy for resectable melanoma reduced recurrence and other clinical events by two-thirds versus adjuvant therapy, a randomized trial showed. Patients treated
June 5, 2024